BCL2L1 and cancer: Using the same approach by which MCL-1 was validated as the key survival factor for MCL-1-amplified cancer cells, BCL-XL was knock-down in cell lines in which BCL-XL was amplified, resulted in a pronounced reduction in viability [51].